Orion Oyj

FI

ORNBV

Health Care

17.5 ₽

Current price

Strong sell
17.5 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    652 / 1328

  • Position in country

    140 / 253

  • Return on Assets, %

    15.8

    -2.7

  • Net income margin, %

    23.3

    2.8

  • EBITDA margin, %

    31.6

    10.8

  • Debt to Equity, %

    22.4

    19.2

  • Intangible assets and goodwill, %

    13.9

    3.6

  • Revenue CAGR 3Y, %

    3.3

    8.5

  • Total Equity change 1Y, %

    1

    0

  • Revenue Y, % chg

    -7.5

    0.5

  • P/E

    21.3

    22.7

  • P/BV

    5.2

    1.5

  • P/S

    3.9

    2.3

  • EV/S

    4

    2.4

  • EV/EBITDA

    14.7

    7.4

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    156.1

    51.3

  • Forward P/E

    19.7

    15.6

  • Dividend Yield, %

    2.4

    1.7

  • Expected dividend per share

    1.8

    0

  • Payout Ratio, %

    103.5

    30.3

  • Dividend Ex Date

    2024-03-21

Get an analytical review of this company

Competitors

Ranks

  • Novo Nordisk A/S

    00%

  • Sanofi SA

    00%

  • AstraZeneca PLC

    00%

  • Eli Lilly and Co

    00%

  • Roche Holding AG

    00%

  • Orion Oyj

    00%

  • Novartis AG

    00%

  • Johnson & Johnson

    00%

  • Merck & Co Inc

    00%

  • Pfizer Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Finland

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Pharmaceuticals

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    5012.4

  • Ticker

    ORINY.PK

  • ISIN

    US68628Y1047

  • IPO date

    2006-07-03

  • Availability on Russian exchanges

    No

  • Reporting for

    2024-02-26

  • Date fact. publication of reports

    2023-12-31

Company Description

Orion Oyj, previously Orion Corporation, is a Finland-based company active within the pharmaceutical industry. The Company is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.